BioCryst Announces New Real-World Evidence for ORLADEYO® at ACAAI 2026
BioCryst Pharmaceuticals presented new real-world evidence demonstrating that patients with hereditary angioedema (HAE) experienced reduced hospitalizations and emergency department visits after initiating or switching to ORLADEYO®.